Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials.

ABSTRACT:

Background

The effects of β blockers on the primary prevention of anthracycline-induced cardiotoxicity were controversial.

Methods

We searched PubMed, Embase and Cochrane Library for randomized controlled trials of the comparison of β blockers versus placebo in patients undergoing anthracycline chemotherapy. This meta-analysis was performed by using random-effect models.

Results

Nine hundred forty participants from 11 trials were included in this meta-analysis. β blockers led to a significant reduction in symptomatic heart failure (risk ratio [RR] 0.29, 95% CI 0.10 to 0.85). Compared with placebo, β blockers were associated with improved left ventricular ejection fraction (mean difference [MD] 4.46, 95% CI 1.77 to 7.15) and s' (MD 0.78, 95% CI 0.01 to 1.55) in paralle

SUBMITTER: Ma Y 

PROVIDER: S-EPMC6485127 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature